Streetbeat News

ALPMY

Astellas Pharma Inc.

https://www.astellas.com/jp/

CEO

Kenji Yasukawa

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

10.08

Mkt cap

18B

Volume

5.6K

High

10.10

P/E Ratio

50.30

52-wk high

13.14

Low

10.06

Div yield

0.05

52-wk low

9.15

Astellas Pharma U.S. has partnered with Desert Oasis Healthcare to pilot DIGITIVA, a digital health solution for heart failure management. This initiative marks the first implementation of DIGITIVA in a health system.

Portfolio Pulse from

November 20, 2024 | 6:15 pm

The article discusses whether value investors should consider buying Astellas Pharma (ALPMY) stock, focusing on the Zacks Rank system which emphasizes earnings estimates and revisions.

Portfolio Pulse from

November 12, 2024 | 4:00 pm

William Blair has initiated coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with an Outperform rating, highlighting the competitive edge of its drug Syfovre in the market for geographic atrophy secondary to age-related macular degeneration. Despite competition from Novartis' Fabhalta, Apellis' Empaveli has significant market opportunities in C3G and IC-MPGN. The analyst projects peak sales for Syfovre to reach $2.0 billion by 2030.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 6:57 pm

Takeda, Astellas, and SMBC have partnered to establish Ciconia Bioventures, a venture focused on early-stage drug discovery in Japan. This collaboration aims to drive innovation in the pharmaceutical sector.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 6:24 am

Astellas has announced the FDA listing of DIGITIVA, a non-invasive digital health solution for heart failure management, allowing patients to monitor their condition at home.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 7:21 am

The European Commission has approved Astellas' PADCEV in combination with KEYTRUDA for the first-line treatment of advanced urothelial cancer. This regimen has shown superiority over the traditional platinum-containing chemotherapy, based on positive results from the Phase 3 EV-302 trial.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 6:53 am

Astellas has initiated a Phase 3 trial for fezolinetant, targeting vasomotor symptoms in women with hormone receptor-positive breast cancer undergoing adjuvant endocrine therapy. The study, named HIGHLIGHT 1™, aims to address moderate to severe symptoms in patients with stage 0-3 cancer.

Portfolio Pulse from Benzinga Newsdesk

August 27, 2024 | 7:15 am

Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:27 pm

Astellas Pharma has received a positive opinion from the CHMP for its drug zolbetuximab, which targets CLDN18.2, for the treatment of advanced gastric and gastroesophageal junction cancer. If approved by the European Commission, it would be the first CLDN18.2-targeted therapy in the EU, with a decision expected by October 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 3:48 pm

Astellas Pharma has received a positive opinion from the CHMP for the approval of PADCEV in combination with KEYTRUDA for the first-line treatment of advanced bladder cancer. This combination could become the first alternative to platinum-containing chemotherapy, showing nearly double the median overall survival in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 3:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.